In the intent to treat analysis , both arms were comparable with respect to adherence to CD4 monitoring visits [ adjusted prevalence risk ratio ( adjPRR ) , 0.98 ; 95 % CI : 0.93 to 1.04 ; P = 0.529 ] , and ART eligibility ( adjPRR , 1.00 ; 95 % CI : 0.77 to 1.31 ; P = 0.946 ) .